Skip to main content
NCBI home page
Philosophical Transactions of the Royal Society B: Biological Sciences logoLink to Philosophical Transactions of the Royal Society B: Biological Sciences
. 2001 Dec 29;356(1416):1905–1913. doi: 10.1098/rstb.2001.1004

RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza.

D Young 1, C Fowler 1, K Bush 1
PMCID: PMC1088568  PMID: 11779391

Abstract

The influenza virus neuraminidase (NA) is important in the pathogenesis of infection and, thus, is an attractive target for agents used in the treatment and prophylaxis of influenza. This article describes preclinical and early clinical data related to RWJ-270201 (BCX-1812), a novel, orally active NA inhibitor that was rationally designed for having potent and selective activity against influenza A and B viruses. RWJ-270201 is a unique NA inhibitor with a cyclopentane ring structure and high selectivity for the influenza NA. RWJ-270201 has efficacy comparable to or better than earlier NA inhibitors against a wide range of influenza A and B isolates, including recently emerged and avian strains, both in vitro and in a lethal murine model of influenza. Based on the high selectivity and efficacy of RWJ-270201 against both type A and B influenza strains in preclinical studies as well as murine pharmacodynamic studies supporting the potential for once-daily administration, clinical trials were initiated in order to determine the tolerability and antiviral activity of RWJ-270201 in humans. To date, clinical studies have indicated that RWJ-270201 is well tolerated and has antiviral activity in human experimental influenza models when administered orally once daily.

Full Text

The Full Text of this article is available as a PDF (156.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Babu Y. S., Chand P., Bantia S., Kotian P., Dehghani A., El-Kattan Y., Lin T. H., Hutchison T. L., Elliott A. J., Parker C. D. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem. 2000 Sep 21;43(19):3482–3486. doi: 10.1021/jm0002679. [DOI] [PubMed] [Google Scholar]
  2. Bantia S., Parker C. D., Ananth S. L., Horn L. L., Andries K., Chand P., Kotian P. L., Dehghani A., El-Kattan Y., Lin T. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother. 2001 Apr;45(4):1162–1167. doi: 10.1128/AAC.45.4.1162-1167.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bossart-Whitaker P., Carson M., Babu Y. S., Smith C. D., Laver W. G., Air G. M. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J Mol Biol. 1993 Aug 20;232(4):1069–1083. doi: 10.1006/jmbi.1993.1461. [DOI] [PubMed] [Google Scholar]
  4. Burmeister W. P., Ruigrok R. W., Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 1992 Jan;11(1):49–56. doi: 10.1002/j.1460-2075.1992.tb05026.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Calfee D. P., Hayden F. G. New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs. 1998 Oct;56(4):537–553. doi: 10.2165/00003495-199856040-00003. [DOI] [PubMed] [Google Scholar]
  6. Colman P. M. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 1994 Oct;3(10):1687–1696. doi: 10.1002/pro.5560031007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Colman P. M., Varghese J. N., Laver W. G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature. 1983 May 5;303(5912):41–44. doi: 10.1038/303041a0. [DOI] [PubMed] [Google Scholar]
  8. Drusano G. L., Preston S. L., Smee D., Bush K., Bailey K., Sidwell R. W. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob Agents Chemother. 2001 Jul;45(7):2115–2118. doi: 10.1128/AAC.45.7.2115-2118.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Govorkova E. A., Leneva I. A., Goloubeva O. G., Bush K., Webster R. G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother. 2001 Oct;45(10):2723–2732. doi: 10.1128/AAC.45.10.2723-2732.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gubareva L. V., Kaiser L., Matrosovich M. N., Soo-Hoo Y., Hayden F. G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis. 2001 Jan 11;183(4):523–531. doi: 10.1086/318537. [DOI] [PubMed] [Google Scholar]
  11. Gubareva L. V., Matrosovich M. N., Brenner M. K., Bethell R. C., Webster R. G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998 Nov;178(5):1257–1262. doi: 10.1086/314440. [DOI] [PubMed] [Google Scholar]
  12. Gubareva L. V., Robinson M. J., Bethell R. C., Webster R. G. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol. 1997 May;71(5):3385–3390. doi: 10.1128/jvi.71.5.3385-3390.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hayden F. G., Hay A. J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol. 1992;176:119–130. doi: 10.1007/978-3-642-77011-1_8. [DOI] [PubMed] [Google Scholar]
  14. Hayden F. G., Osterhaus A. D., Treanor J. J., Fleming D. M., Aoki F. Y., Nicholson K. G., Bohnen A. M., Hirst H. M., Keene O., Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med. 1997 Sep 25;337(13):874–880. doi: 10.1056/NEJM199709253371302. [DOI] [PubMed] [Google Scholar]
  15. Kim C. U., Lew W., Williams M. A., Liu H., Zhang L., Swaminathan S., Bischofberger N., Chen M. S., Mendel D. B., Tai C. Y. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc. 1997 Jan 29;119(4):681–690. doi: 10.1021/ja963036t. [DOI] [PubMed] [Google Scholar]
  16. Liu C., Eichelberger M. C., Compans R. W., Air G. M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol. 1995 Feb;69(2):1099–1106. doi: 10.1128/jvi.69.2.1099-1106.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. McKimm-Breschkin J. L. Resistance of influenza viruses to neuraminidase inhibitors--a review. Antiviral Res. 2000 Jul;47(1):1–17. doi: 10.1016/s0166-3542(00)00103-0. [DOI] [PubMed] [Google Scholar]
  18. Meindl P., Bodo G., Palese P., Schulman J., Tuppy H. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology. 1974 Apr;58(2):457–463. doi: 10.1016/0042-6822(74)90080-4. [DOI] [PubMed] [Google Scholar]
  19. Peiris M., Yuen K. Y., Leung C. W., Chan K. H., Ip P. L., Lai R. W., Orr W. K., Shortridge K. F. Human infection with influenza H9N2. Lancet. 1999 Sep 11;354(9182):916–917. doi: 10.1016/s0140-6736(99)03311-5. [DOI] [PubMed] [Google Scholar]
  20. Sidwell R. W., Smee D. F., Huffman J. H., Barnard D. L., Bailey K. W., Morrey J. D., Babu Y. S. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob Agents Chemother. 2001 Mar;45(3):749–757. doi: 10.1128/AAC.45.3.749-757.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Smee D. F., Huffman J. H., Morrison A. C., Barnard D. L., Sidwell R. W. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother. 2001 Mar;45(3):743–748. doi: 10.1128/AAC.45.3.743-748.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., Perdue M., Swayne D., Bender C., Huang J. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science. 1998 Jan 16;279(5349):393–396. doi: 10.1126/science.279.5349.393. [DOI] [PubMed] [Google Scholar]
  23. Tai C. Y., Escarpe P. A., Sidwell R. W., Williams M. A., Lew W., Wu H., Kim C. U., Mendel D. B. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother. 1998 Dec;42(12):3234–3241. doi: 10.1128/aac.42.12.3234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Treanor J. J., Hayden F. G., Vrooman P. S., Barbarash R., Bettis R., Riff D., Singh S., Kinnersley N., Ward P., Mills R. G. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000 Feb 23;283(8):1016–1024. doi: 10.1001/jama.283.8.1016. [DOI] [PubMed] [Google Scholar]
  25. Varghese J. N., McKimm-Breschkin J. L., Caldwell J. B., Kortt A. A., Colman P. M. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins. 1992 Nov;14(3):327–332. doi: 10.1002/prot.340140302. [DOI] [PubMed] [Google Scholar]
  26. von Itzstein M., Wu W. Y., Kok G. B., Pegg M. S., Dyason J. C., Jin B., Van Phan T., Smythe M. L., White H. F., Oliver S. W. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993 Jun 3;363(6428):418–423. doi: 10.1038/363418a0. [DOI] [PubMed] [Google Scholar]

Articles from Philosophical Transactions of the Royal Society of London. Series B are provided here courtesy of The Royal Society

RESOURCES